Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban

Compared with rivaroxaban, the use of dabigatran may be associated with a lower risk of cancer-related death and all-cause mortality.